Angiotensin II receptor type 1 blocker candesartan improves morphine tolerance by reducing morphine‑induced inflammatory response and cellular activation of BV2 cells via the PPARγ/AMPK signaling pathway

Zhao,Wenxin; Shen,Feiyan; Yao,Jixiang; Su,Shanshan; Zhao,Zhongmin

doi:10.3892/mmr.2022.12834

Angiotensin II receptor type 1 blocker candesartan improves morphine tolerance by reducing morphine‑induced inflammatory response and cellular activation of BV2 cells via the PPARγ/AMPK signaling pathway

Authors:
- Wenxin Zhao
- Feiyan Shen
- Jixiang Yao
- Shanshan Su
- Zhongmin Zhao
View Affiliations

Affiliations: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100020, P.R. China, Changchun University of Chinese Medicine, Changchun, Jilin 130117, P.R. China, Department of Pain Management, Affiliated Hospital 5 of Nantong University (Taizhou People's Hospital), Taizhou, Jiangsu 225300, P.R. China
Published online on: August 25, 2022 https://doi.org/10.3892/mmr.2022.12834
Article Number: 318
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Morphine is the most common drug of choice in clinical pain management; however, morphine tolerance presents a significant clinical challenge. The pathogenesis of morphine tolerance is known to be closely associated with angiotensin II receptor type 1 (AT1R) in microglia. As an AT1R antagonist, candesartan may serve an important role in regulating morphine tolerance. Therefore, the present study aimed to investigate the role of candesartan in morphine tolerance, and to explore the underlying mechanism. To meet this aim, BV2 microglial cells were treated with morphine or candesartan alone, or as a combination, and the expression levels of AT1R in BV2 cells were detected by reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting. The levels of the inflammatory cytokines tumor necrosis factor‑α, interleukin (IL)‑1β and IL‑6 were subsequently detected by ELISA and western blotting. In addition, immunofluorescence analysis, western blotting and RT‑qPCR were used to detect the expression levels of the BV2 cell activation marker, ionized calcium‑binding adaptor molecule 1 (IBA‑1). Western blotting was also used to detect the expression levels of peroxisome proliferator‑activated receptor‑γ/AMP‑activated protein kinase (PPARγ/AMPK) signaling pathway‑associated proteins. Finally, the cells were treated with the PPARγ antagonist GW9662 and the AMPK inhibitor compound C to further explore the mechanism underlying the effects of candesartan on improving morphine tolerance. The expression levels of AT1R were revealed to be significantly increased following morphine induction; however, candesartan treatment inhibited the expression levels of AT1R, the levels of inflammatory cytokines and the protein expression levels of IBA‑1 in morphine‑induced BV2 cells in a dose‑dependent manner. These processes may be associated with activation of the PPARγ/AMPK signaling pathway. Taken together, the present study revealed that treatment with candesartan reduced morphine‑induced inflammatory response and cellular activation of BV2 cells via PPARγ/AMPK signaling.

View Figures

View References

1	Zhang TJ, Qiu Y and Hua Z: The emerging perspective of morphine tolerance: MicroRNAs. Pain Res Manag. 2019:94329652019. View Article : Google Scholar : PubMed/NCBI
2	Kornetsky C and Bain G: Morphine: Single-dose tolerance. Science. 162:1011–1012. 1968. View Article : Google Scholar : PubMed/NCBI
3	Schaefer CP, Tome ME and Davis TP: The opioid epidemic: A central role for the blood brain barrier in opioid analgesia and abuse. Fluids Barriers CNS. 14:322017. View Article : Google Scholar : PubMed/NCBI
4	Martini L and Whistler JL: The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol. 17:556–564. 2007. View Article : Google Scholar : PubMed/NCBI
5	Huang M, Luo L, Zhang Y, Wang W, Dong J, Du W, Jiang W and Xu T: Metabotropic glutamate receptor 5 signalling induced NMDA receptor subunits alterations during the development of morphine-induced antinociceptive tolerance in mouse cortex. Biomed Pharmacother. 110:717–726. 2019. View Article : Google Scholar : PubMed/NCBI
6	Jokinen V, Sidorova Y, Viisanen H, Suleymanova I, Tiilikainen H, Li Z, Lilius TO, Mätlik K, Anttila JE, Airavaara M, et al: Differential spinal and supraspinal activation of Glia in a rat model of morphine tolerance. Neuroscience. 375:10–24. 2018. View Article : Google Scholar : PubMed/NCBI
7	Eidson LN and Murphy AZ: Inflammatory mediators of opioid tolerance: Implications for dependency and addiction. Peptides. 115:51–58. 2019. View Article : Google Scholar : PubMed/NCBI
8	Lin CP and Lu DH: Role of neuroinflammation in opioid tolerance: Translational evidence from human-to-rodent studies. Adv Exp Med Biol. 1099:125–139. 2018. View Article : Google Scholar : PubMed/NCBI
9	Berrios I, Castro C and Kuffler DP: Morphine: Axon regeneration, neuroprotection, neurotoxicity, tolerance, and neuropathic pain. P R Health Sci J. 27:119–128. 2008.PubMed/NCBI
10	Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB, Rezvani N, Baker EM, Jekich BM, Wieseler JL, Somogyi AA, et al: Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun. 22:1178–1189. 2008. View Article : Google Scholar : PubMed/NCBI
11	Miyoshi M, Miyano K, Moriyama N, Taniguchi M and Watanabe T: Angiotensin type 1 receptor antagonist inhibits lipopolysaccharide-induced stimulation of rat microglial cells by suppressing nuclear factor kappaB and activator protein-1 activation. Eur J Neurosci. 27:343–351. 2008. View Article : Google Scholar : PubMed/NCBI
12	Chappell MC: Biochemical evaluation of the renin-angiotensin system: The good, bad, and absolute? Am J Physiol Heart Circ Physiol. 310:H137–H152. 2016. View Article : Google Scholar : PubMed/NCBI
13	Ji J, Tao P and He L: Kangxianling decoction prevents renal fibrosis in rats with 5/6 nephrectomy and inhibits Ang II-induced ECM production in glomerular mesangial cells. J Pharmacol Sci. 139:367–372. 2019. View Article : Google Scholar : PubMed/NCBI
14	Labandeira-Garcia JL, Rodriguez-Perez AI, Garrido-Gil P, Rodriguez-Pallares J, Lanciego JL and Guerra MJ: Brain renin-angiotensin system and microglial polarization: Implications for aging and neurodegeneration. Front Aging Neurosci. 9:1292017. View Article : Google Scholar : PubMed/NCBI
15	Rodriguez-Perez AI, Borrajo A, Rodriguez-Pallares J, Guerra MJ and Labandeira-Garcia JL: Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation. Glia. 63:466–482. 2015. View Article : Google Scholar : PubMed/NCBI
16	Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ and Labandeira-Garcia JL: The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: Relevance to progression of the disease. J Neurochem. 109:656–669. 2009. View Article : Google Scholar : PubMed/NCBI
17	Rey P, Lopez-Real A, Sanchez-Iglesias S, Muñoz A, Soto-Otero R and Labandeira-Garcia JL: Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol Aging. 28:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
18	Rodriguez-Pallares J, Rey P, Parga JA, Muñoz A, Guerra MJ and Labandeira-Garcia JL: Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis. 31:58–73. 2008. View Article : Google Scholar : PubMed/NCBI
19	Bulsara KG and Makaryus AN: Candesartan. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022
20	Qie S, Ran Y, Lu X, Su W, Li W, Xi J, Gong W and Liu Z: Candesartan modulates microglia activation and polarization via NF-κB signaling pathway. Int J Immunopathol Pharmacol. 34:20587384209749002020. View Article : Google Scholar : PubMed/NCBI
21	Timaru-Kast R, Gotthardt P, Luh C, Huang C, Hummel R, Schäfer MKE and Thal SC: Angiotensin II receptor 1 blockage limits brain damage and improves functional outcome after brain injury in aged animals despite age-dependent reduction in AT1 Expression. Front Aging Neurosci. 11:632019. View Article : Google Scholar : PubMed/NCBI
22	Wang L, Yin C, Xu X, Liu T, Wang B, Abdul M, Zhou Y, Cao J and Lu C: Pellino1 contributes to morphine tolerance by microglia activation via MAPK signaling in the spinal cord of mice. Cell Mol Neurobiol. 40:1117–1131. 2020. View Article : Google Scholar : PubMed/NCBI
23	Torika N, Asraf K, Apte RN and Fleisher-Berkovich S: Candesartan ameliorates brain inflammation associated with Alzheimer's disease. CNS Neurosci Ther. 24:231–242. 2018. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Stein C: New concepts in opioid analgesia. Expert Opin Investig Drugs. 27:765–775. 2018. View Article : Google Scholar : PubMed/NCBI
26	Sverrisdottir E, Lund TM, Olesen AE, Drewes AM, Christrup LL and Kreilgaard M: A review of morphine and morphine-6-glucuronide's pharmacokinetic-pharmacodynamic relationships in experimental and clinical pain. Eur J Pharm Sci. 74:45–62. 2015. View Article : Google Scholar : PubMed/NCBI
27	Mercadante S, Arcuri E and Santoni A: Opioid-induced tolerance and hyperalgesia. CNS Drugs. 33:943–955. 2019. View Article : Google Scholar : PubMed/NCBI
28	Selfridge BR, Wang X, Zhang Y, Yin H, Grace PM, Watkins LR, Jacobson AE and Rice KC: Structure-activity relationships of (+)-naltrexone-inspired toll-like receptor 4 (TLR4) antagonists. J Med Chem. 58:5038–5052. 2015. View Article : Google Scholar : PubMed/NCBI
29	Hickman SE, el Khoury J, Greenberg S, Schieren I and Silverstein SC: P2Z adenosine triphosphate receptor activity in cultured human monocyte-derived macrophages. Blood. 84:2452–2456. 1994. View Article : Google Scholar : PubMed/NCBI
30	Lim KH and Staudt LM: Toll-like receptor signaling. Cold Spring Harb Perspect Biol. 5:a0112472013. View Article : Google Scholar : PubMed/NCBI
31	Bernier LP: Purinergic regulation of inflammasome activation after central nervous system injury. J Gen Physiol. 140:571–575. 2012. View Article : Google Scholar : PubMed/NCBI
32	Eidson LN and Murphy AZ: Blockade of Toll-like receptor 4 attenuates morphine tolerance and facilitates the pain relieving properties of morphine. J Neurosci. 33:15952–15963. 2013. View Article : Google Scholar : PubMed/NCBI
33	Wang H, Huang M, Wang W, Zhang Y, Ma X, Luo L, Xu X, Xu L, Shi H, Xu Y, et al: Microglial TLR4-induced TAK1 phosphorylation and NLRP3 activation mediates neuroinflammation and contributes to chronic morphine-induced antinociceptive tolerance. Pharmacol Res. 165:1054822021. View Article : Google Scholar : PubMed/NCBI
34	Wang H, Zhang Y, Ma X, Wang W, Xu X, Huang M, Xu L, Shi H, Yuan T, Jiang W, et al: Spinal TLR4/P2X7 receptor-dependent NLRP3 inflammasome activation contributes to the development of tolerance to morphine-induced antinociception. J Inflamm Res. 13:571–582. 2020. View Article : Google Scholar : PubMed/NCBI
35	Biancardi VC, Stranahan AM, Krause EG, de Kloet AD and Stern JE: Cross talk between AT1 receptors and Toll-like receptor 4 in microglia contributes to angiotensin II-derived ROS production in the hypothalamic paraventricular nucleus. Am J Physiol Heart Circ Physiol. 310:H404–H415. 2016. View Article : Google Scholar : PubMed/NCBI
36	Sun H, Wu H, Yu X, Zhang G, Zhang R, Zhan S, Wang H, Bu N, Ma X and Li Y: Angiotensin II and its receptor in activated microglia enhanced neuronal loss and cognitive impairment following pilocarpine-induced status epilepticus. Mol Cell Neurosci. 65:58–67. 2015. View Article : Google Scholar : PubMed/NCBI
37	Rodriguez-Perez AI, Garrido-Gil P, Pedrosa MA, Garcia-Garrote M, Valenzuela R, Navarro G, Franco R and Labandeira-Garcia JL: Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra. Brain Behav Immun. 87:256–271. 2020. View Article : Google Scholar : PubMed/NCBI
38	Chandel N, Sharma B, Salhan D, Husain M, Malhotra A, Buch S and Singhal PC: Vitamin D receptor activation and downregulation of renin-angiotensin system attenuate morphine-induced T cell apoptosis. Am J Physiol Cell Physiol. 303:C607–C615. 2012. View Article : Google Scholar : PubMed/NCBI
39	Bhat SA, Goel R, Shukla R and Hanif K: Angiotensin receptor blockade modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation better than angiotensin-converting enzyme inhibition. Mol Neurobiol. 53:6950–6967. 2016. View Article : Google Scholar : PubMed/NCBI
40	Tiyerili V, Becher UM, Aksoy A, Lütjohann D, Wassmann S, Nickenig G and Mueller CF: AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ. Cardiovasc Diabetol. 12:302013. View Article : Google Scholar : PubMed/NCBI
41	de Guglielmo G, Kallupi M, Scuppa G, Stopponi S, Demopulos G, Gaitanaris G and Ciccocioppo R: Analgesic tolerance to morphine is regulated by PPARγ. Br J Pharmacol. 171:5407–5416. 2014. View Article : Google Scholar : PubMed/NCBI
42	Ghavimi H, Hassanzadeh K, Maleki-Dizaji N, Azarfardian A, Ghasami S, Zolali E and Charkhpour M: Pioglitazone prevents morphine antinociception tolerance and withdrawal symptoms in rats. Naunyn Schmiedebergs Arch Pharmacol. 387:811–821. 2014. View Article : Google Scholar : PubMed/NCBI
43	Xu X, Wang Y, Wei Z, Wei W, Zhao P, Tong B, Xia Y and Dai Y: Madecassic acid, the contributor to the anti-colitis effect of madecassoside, enhances the shift of Th17 toward Treg cells via the PPARγ/AMPK/ACC1 pathway. Cell Death Dis. 8:e27232017. View Article : Google Scholar : PubMed/NCBI
44	Huang H, Wang ZJ, Zhang HB, Liang JX, Cao WD, Wu Q, He CP and Chen C: The function of PPARγ/AMPK/SIRT-1 pathway in inflammatory response of human articular chondrocytes stimulated by advanced glycation end products. Biol Pharm Bull. 42:1303–1309. 2019. View Article : Google Scholar : PubMed/NCBI
45	Chao YM, Wu KLH, Tsai PC, Tain YL, Leu S, Lee WC and Chan JYH: Anomalous AMPK-regulated angiotensin AT1R expression and SIRT1-mediated mitochondrial biogenesis at RVLM in hypertension programming of offspring to maternal high fructose exposure. J Biomed Sci. 27:682020. View Article : Google Scholar : PubMed/NCBI
46	Zhao Y, Shang F, Shi W, Zhang J, Zhang J, Liu X, Li B, Hu X and Wang L: Angiotensin II receptor type 1 antagonists modulate vascular smooth muscle cell proliferation and migration via AMPK/mTOR. Cardiology. 143:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
47	Shu S, Zhang Y, Li W, Wang L, Wu Y, Yuan Z and Zhou J: The role of monocyte chemotactic protein-induced protein 1 (MCPIP1) in angiotensin II-induced macrophage apoptosis and vulnerable plaque formation. Biochem Biophys Res Commun. 515:378–385. 2019. View Article : Google Scholar : PubMed/NCBI
48	Zhang Y, Tao GJ, Hu L, Qu J, Han Y, Zhang G, Qian Y, Jiang CY and Liu WT: Lidocaine alleviates morphine tolerance via AMPK-SOCS3-dependent neuroinflammation suppression in the spinal cord. J Neuroinflammation. 14:2112017. View Article : Google Scholar : PubMed/NCBI